ABINGDON-HEALTH-PLC
16.2.2021 11:54:06 CET | Business Wire | Press release
Abingdon Health plc (“the Company”), a leading international developer and manufacturer of high quality and effective rapid tests, announces that the AbC-19™ Rapid Test for the detection of SARS-CoV-2 antibodies is now available for purchase by healthcare professionals on the Abingdon Health website .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005611/en/
The AbC-19™ Rapid Test is a self-contained, highly accurate lateral flow immunoassay designed to give results within 20 minutes at the point of use. The test is designed to confirm the presence of IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus. These are the type of antibodies which neutralise the virus and can produce immunity as found after vaccination or following an immune response to COVID-19. The attached image explains the AbC-19™ Rapid Test Process.
Deployed at scale across populations, the test can aid policymakers, healthcare systems, the scientific community, and the public at large by:
- Assisting health providers, researchers, and governments in understanding the extent of the SARS-CoV-2 infection and its spread through communities (seroprevalence)
- Enabling researchers to understand whether people are developing immunity
- Informing the development and evaluation of large-scale vaccine tests, and eventual mass immunisation campaigns.
The AbC-19™ Rapid Test has demonstrated high levels of sensitivity and specificity in a clinical setting. Evaluation studies involving 880 patient samples showed sensitivity of 97.58% (95% confidence level 95.28%-98.95%) and specificity of 99.59% (95% confidence interval 98.53%-99.95%). Further details of this study can be found online at MedRxiv .
The AbC-19™ Rapid Test can be purchased by health professionals on the Abingdon Health website .
Leigh Thomas, SVP Director of Global Sales of Abingdon Health, commented: “Research has underlined the pivotal role of the SARS-CoV-2 Spike protein – and the body’s response to it – in developing immunity to COVID-19. As efforts intensify to build large-scale immunity to the virus, we are confident that the AbC-19™ Rapid Test, an easy-to-use antibody test suitable for use outside of the laboratory by healthcare professionals, will be an invaluable tool in the toolbox in the fight against the virus.”
Please note AbC-19™ Rapid Test is available for professional use only and not for self-testing.
About Abingdon Health plc
Abingdon Health plc is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx® , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. Founded in 2008, Abingdon Health is headquartered in York, England.
https://www.abingdonhealth.com/
AbC-19TM Rapid Test
The Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005611/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform31.3.2026 12:00:00 CEST | Press release
Round Led by Collaborative Fund with Participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Cristiano Ronaldo, LeBron James, Rory McIlroy WHOOP, the human performance company, today announced it has raised $575 million in Series G funding at a $10.1 billion valuation, advancing its global expansion and long-term vision for personalized health. The round was led by Collaborative Fund and includes global participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Macquarie Capital (entities administered by Macquarie Capital), Glade Brook, B-Flexion, IVP, Foundry, Accomplice, Affinity Partners, Promus Ventures, and Bullhound Capital alongside a group of prominent global athletes and individual investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331399622/en/ WHOOP Raises $575 Million at $10.1 B
Interactive Brokers Launches Crypto-Asset Trading for Individual Investors in the European Economic Area31.3.2026 11:00:00 CEST | Press release
Eligible clients can now trade 11 popular crypto-assets including Bitcoin and Ethereum alongside stocks, options, futures, and more, all from a single, integrated platform Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of crypto-asset trading for eligible individual investors in the EEA through Interactive Brokers Ireland Limited, which is an authorised crypto-asset service provider in the EEA. Many European investors face challenges managing multiple crypto apps, understanding unclear fees, or navigating security concerns. Interactive Brokers now offers a solution. Starting today, eligible individual investors in the EEA can trade 11 leading crypto-assets directly on the same platform they already use for stocks, options, futures, currencies, bonds, and mutual funds. This integrated approach gives clients a unified view of their entire portfolio. With one login, they can manage both traditional and crypto-assets, backed by the control, low p
Philip Morris International Presents its Value Report 2025: change in motion31.3.2026 10:30:00 CEST | Press release
The company’s annual disclosure unveils its Value Plan 2030+ Philip Morris International (NYSE: PM) today released its Value Report 2025, offering a holistic perspective on the company’s approach to sustainable value creation. The report marks the completion of PMI’s 2025 Roadmap, communicating achievements for each aspiration introduced by the company in 2020, and introduces its Value Plan 2030+, set to guide the company’s continued path to sustainable growth. “For more than a decade, PMI has pursued an industry-leading shift away from cigarettes—a transformation that goes far beyond product innovation to encompass how we allocate capital, engage stakeholders, and measure success,” said Jacek Olczak, Group Chief Executive Officer. “‘change in motion’ captures the reality that transformation is not a project with a defined end date, it is the continuous work of improvement, innovation, and adaptation that keeps us relevant and resilient. We transform continuously because markets evolve
BarmeniaGothaer Modernizes Front-to-Back Investment Platform with Bloomberg and Clearwater Analytics31.3.2026 10:00:00 CEST | Press release
Unified data and a total portfolio view across public and private assets improves transparency, risk oversight, and investment decision-making Bloomberg and Clearwater Analytics (NYSE: CWAN) today announced that BarmeniaGothaer Asset Management AG, one of Germany’s top 10 insurance asset managers managing more than 50 billion euros in assets, has gone live on Bloomberg’s buy-side solutions and has selected Clearwater Analytics as its middle- and back-office management platform, including accounting and data management, completing its front-to-back investment transformation across the organization. The merger of Barmenia and Gothaer in 2024 has created the opportunity to successfully unite two distinct technology and data environments, thereby advancing investment management to a new level. By integrating Bloomberg’s buy-side solutions and Clearwater Analytics into its operations, BarmeniaGothaer Asset Management AG is creating a future-proof investment management workflow that meets th
TREASoURcE Final Conference: 14 April 2026, Brussels – Circular Systemic Solutions: From Demos to Deployment31.3.2026 09:32:00 CEST | Press release
The EU-funded project brings policymakers, industry and cities together to discuss how circular economy solutions can scale beyond pilots. The EU-funded TREASoURcE project will present its key results and policy messages at the Final Conference on 14 April 2026 in Brussels, bringing together policymakers, industry representatives, researchers, cities and civil society actors from across Europe. The full-day conference focuses on how circular economy solutions can move from pilot projects to broader deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331360899/en/ Join us in Brussels for the TREASoURcE Final Conference on circular solutions. Over four years, TREASoURcE has developed and tested scalable circular solutions across three value chains: plastics, batteries, and biobased side and waste streams. From demonstrations to deployment: addressing Europe’s scaling challenge The final conference responds to one of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom